News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Jardiance Weight Loss: Newly Launch Over the Counter Alternative Pills To Jardiance Weight Loss Medication

Allied PR

Healthcare professionals frequently recommend the medication Jardiance to individuals with diabetes. Medical practitioners and specialists contend that it additionally assists individuals encountering challenges with weight management issues. Click Here to Buy Legal Jardiance Formula OTC such as PhenGold. It is widely acknowledged that maintaining physical fitness and good health is of paramount significance. The escalating expenses of healthcare and hospitalization have rendered them increasingly unaffordable on a global scale. Therefore, individuals strive to mitigate any health-related expenses that are within their means to circumvent. This report provides an analysis of the top five dietary supplements that are known to aid individuals in maintaining physical fitness. These dietary products purportedly offer assistance in shedding surplus weight and maintaining physical well-being. What are the best 5 Over The Counter Alternatives to Jardiance Weight Loss Medication? This article aims to conduct a comprehensive analysis of the five most effective dietary supplements available in the market for facilitating weight management. These supplements are capable of aiding individuals in the natural and efficient management of their body weight. These dietary supplements are formulated with naturally sourced and organically derived constituents, purportedly yielding beneficial outcomes. Presented below are the quintessential quintet of weight management supplements, which are presently leading the market. PhenGold - Top Choice for Jardiance Alternative OTC PhenQ - Strongest OTC Jardiance Weight Loss Alternative Capsiplex BURN - Best Choice for Men to Jardiance Alternative Trimtone - Best Choice for Women to Jardiance Alternative PrimeShred - Best Fat Burner for Men to Jardiance Alternative 1. PhenGold - Top Choice for Jardiance Alternative OTC PhenGold can be effective for those who have trouble controlling their weight. It is a fantastic health supplement that can support people in their efforts to lose weight. People can keep up a good exercise and diet routine with the aid of its special formula. Click Here to Buy PhenGold From The Official Website Ingredients To assist people in controlling their weight, PhenGold uses an entirely natural formula. Various herbs, plants, and spices are included in the recipe. It also has beneficial nutrients that support maintaining the body's health and nourishment. The main components are listed below: Green Tea and Coffee L-Tyrosine L-Theanine Cayenne Rhodiola rosea B-Complex vitamins Caffeine DMAE Working Managing one's weight can be done with the aid of the specialized health supplement PhenGold. People can stay fit and healthy thanks to it. Here are some advantages: It aids in increasing the body's basal metabolic rate, facilitating faster fat burning. Its components aid in reducing cravings for food. People may feel more energised as a result. Negative Effects The professionals behind PhenGold are aware of how vital human health is. Their research indicates that PhenGold has no known or discernible side effects. However, people should speak with a reputable and experienced doctor before taking any supplements. Such a doctor's recommendations may be helpful. People in the following categories ought to exercise extra caution: Women who are expecting or nursing Individuals who suffer from long-term illnesses People who are allergic to any of the ingredients Children under the age of 18 Dosage People should exercise caution and only consume supplements in the recommended dosage. Three pills taken 20 minutes prior to breakfast each day is the recommended dosage for PhenGold. Regarding doses of supplements, people should heed medical advice. Purchase and Price Beyond the official website, people won't be able to find PhenGold anywhere else online. This supplement is also not available in any physical stores. This stringent procedure guarantees high-quality goods. The 90 capsules in each bottle of PhenGold are good for one month. These are the costs: One bottle costs USD 59.99. Three bottles cost US$119.999. Five bottles cost US$179.99. Money back Policy The components of PhenGold have undergone extensive testing by qualified scientists, as was previously mentioned. There is strong evidence that PhenGold can fulfill its promises. Online, it's simple to find a number of positive product reviews. But users need not worry if they are dissatisfied with the product. All official purchases are covered by a 100% money-back guarantee policy for 100 days. 2. PhenQ - Strongest OTC Jardiance Weight Loss Alternative PhenQ is a dietary supplement that purports to aid individuals in achieving weight loss through natural means. According to its manufacturers, this product purportedly enhances the body's ability to metabolize food. The methodology entails a dual modality strategy that enhances metabolic activity while concurrently quelling appetite. PhenQ constitutes a distinct dietary supplement that may yield favorable outcomes and assist individuals in achieving a leaner physique. Consistent PhenQ usage yields favorable outcomes in the long term. (ACT NOW & SAVE) Click Here to GET PhenQ From The Official Website Ingredients PhenQ is a highly efficacious dietary supplement that facilitates weight loss among individuals. It employs a unique formulation consisting solely of natural ingredients. PhenQ is absent of any synthetic ingredients or preserving agents that could impede its efficacy. It comprises constituents derived from diverse efficacious botanical herbs, plants, and spices. Presented below are the primary constituents comprising PhenQ: Alpha Lacys Reset. Capsimax Nopal cactus Chromium picolinate L-carnitine fumarate Caffeinated substances. Working The diverse constituents of PhenQ facilitate the regulation of the body's metabolism. The organic composition aids individuals in regulating their weight and eliminating resilient adipose tissue. It confers various benefits upon the body, including the following: It has the potential to enhance the efficiency of metabolic processes. As a result, it enhances the rate of nutrient absorption within the body. It can provide the body with a surge of vitality, which enables individuals to engage in more rigorous physical exercise. Hence, it can facilitate individuals to enhance their physical activity regimen. This product has the potential to enhance the body's metabolic processes across multiple pathways. It has the potential to facilitate the selective reduction of adipose tissue accumulation in the body over an extended period. It has the potential to enhance individuals' dietary habits and mitigate their inclination towards food temptations. The constituents of this product aid in promoting satiety post-consumption, thereby diminishing appetite. Furthermore, it has the potential to enhance individuals' emotional state. Read: Mounjaro Weight Loss Side Effects There exists no discernible nor observable adverse repercussions or aftermaths of regular usage of PhenQ. Nonetheless, individuals desiring to utilize this supplement ought to seek guidance from a medical practitioner. Given the potential impact of a supplement on diverse biological mechanisms, it is advisable to solicit professional guidance. Individuals belonging to the subsequent categories should exercise particular caution: Individuals who exhibit hypersensitivity to the constituents Individuals who suffer from persistent health ailments Women who are in a state of pregnancy or lactation Individuals below the age of 18 years Dosage PhenQ is a remarkable dietary supplement that has the potential to enhance the quality of life of the individuals who consume it. Nonetheless, the impact is contingent upon the regular dosage consumed by individuals. As per the guidelines provided on the official website, it is recommended to consume two pills on a daily basis. It is recommended that the initial dose be taken prior to breakfast, followed by a subsequent dose ahead of lunch. Notwithstanding, it is imperative that individuals adhere to medical guidance in case a physician suggests an alternative measure. Purchase and Price Prospective buyers of PhenQ are advised to seek its availability via online channels. It is solely accessible through the website designated by the product manufacturer. It is not available in any brick-and-mortar retail outlets. The implementation of such measures serves to safeguard customers from the negative effects of counterfeit products. Each bottle consists of 60 pills and is designed to provide a month's supply. Please find below the stipulated rates: A singular unit of the product is priced at USD 69.99. Three bottles are available for purchase at a cost of USD 139.99. The cost of five bottles is two hundred nine dollars and ninety-nine cents. Refund Policy PhenQ exclusively incorporates premium and highly efficacious components in its all-natural formulation. Research findings demonstrate the beneficial effects of these constituents on human beings. In addition to empirical investigations, the perspectives of end-users furnish ample evidence that PhenQ is efficacious. Nevertheless, in the event that consumers perceive the product to be ineffective, they can rest assured. All authorized purchases from the official website are supported by a refund policy that guarantees a 100% return of the purchase price. Customers are granted a period of 60 days from the date of purchase to submit their queries to the designated support channel at support@phenq.com. 3. Capsiplex BURN - Best Choice for Men to Jardiance Alternative Capsiplex Burn is a dietary supplement designed to enhance metabolism and facilitate the preservation of muscle mass for the purpose of reducing body weight. Per the manufacturer's recommendations, the consumption of three capsules daily can assist in the sculpting of a lean physique, the reduction of adipose tissue, and the maintenance of skeletal muscle mass. The substances incorporated in the formula function to subdue the sensation of hunger and satiation, resulting in a reduction in caloric consumption and a boost in weight reduction. Click Here to Buy Capsiplex BURN From The Official Website The dietary capsules function by promoting weight reduction through both thermogenesis and non-thermogenic mechanisms. As per the information provided on the authorized website, utilization of Capsiplex Burn empowers the individuals to effortlessly attain their weight reduction objectives by replenishing their body for physical exertion. Furthermore, the capsules serve to regulate mood, ameliorate stress, and enhance motivation in the pursuit of weight loss. Working Capsiplex Burn has been formulated with the objective of facilitating consumers to effortlessly undergo the cutting phase. Reducing one's weight requires an unwavering commitment to managing one's food intake, with or without the aid of physical exertion. During the process of shedding pounds through a non-exertion method, individuals may encounter fatigue, appetite fluctuations, and changes in emotional stability. Conversely, employing burn to reduce weight amplifies the efficacy of the cutting process by curbing hunger pangs and carbohydrate cravings, leading to superior outcomes in fat incineration. Consumers who utilize Capsiplex Burn are able to acquire amino acids that act as precursors for pivotal neurotransmitters, which assist in heightening energy levels, mitigating stress, and augmenting cognitive acuity. Consequently, the aforementioned formula counteracts weariness and fosters impetus towards engaging in physical exertion. Additionally, the nutritional supplement incorporates exclusive supplements that enhance the metabolism of fats, carbohydrates, and proteins, as it has been patented. Certain constituents elicit the stimulation of thyroid hormone synthesis, which promotes metabolic processes. Capsiplex capsules demonstrate inhibitory effects on glucose absorption and exert regulatory influence on the catabolism of fatty acids. Ingredients Innoslim Capsimax Caffeine Vitamin B Potassium Iodide Chromium Picolinate L-Arginine HCL L-Tyrosine Piperine Dosage Pricing Customers have the ability to place an order for Capsiplex Burn at a reduced rate through the official website in the following manner: Take advantage of our introductory offer and obtain a single bottle at the affordable price of $64.99, inclusive of complimentary shipping. Our most frequently purchased package offers a special deal of three bottles for the price of two, at the cost of $129.99 and also includes complimentary shipping. The most significant cost-saving offer entails the purchase of three bottles, with an additional benefit of two complimentary bottles, totaling to $194.99 with the added convenience of free shipping. Please follow the link provided below to avail a discounted price on Capsiplex Burn. Complimentary shipping is extended to all packages, with a delivery timeframe of up to five working days in both the United States and the United Kingdom. Notwithstanding, consignments sent overseas require a maximum of 14 working days for delivery. Furthermore, the producer offers a pledge to customers of a safe and protected payment process. Refund Policy In the event of consumer dissatisfaction, a complete reimbursement may be sought within the first 60 days subsequent to the purchase, provided that the bottles are returned unused. The Capsiplex Burn formula is supported by a 60-day refund policy. Pricing Patrons can procure Capsiplex Burn from the official website at reduced rates that are enumerated below: Purchase a single bottle at the price of $64.99 with no additional shipping charges. The most popular package, comprising two bottles, is currently available for a price of $129.99 with the added benefit of receiving one additional bottle at no cost to you. Moreover, this offer includes free shipping. The most significant cost-effective package deal: Purchase three bottles and receive an additional two at no charge for a total price of $194.99, including complimentary shipping. All consignments are dispatched without any shipping charges, and shipments are typically delivered within five business days across the United States and United Kingdom. Nevertheless, the delivery of international consignments may require a maximum of 14 business days. Moreover, the manufacturer provides an assurance to its customers regarding a secure transaction at the checkout. Refund Policy Purchasers dissatisfied with the outcomes may request a complete reimbursement within a period of 60 days subsequent to acquisition while also returning the unused containers. The formula is comprehensively supported by a money-back guarantee that extends up to a period of 60 days. 4. TrimTone - Best Choice for Women to Jardiance Alternative Trimtone is a dietary supplement composed entirely of natural ingredients, devised to serve as a fat-burning agent targeted toward the female demographic. Click Here to Order Trimtone for the Best Price Available! Why only for women? The manufacturers are cognizant of the fact that there is a discrepancy in weight loss patterns between males and females. Furthermore, empirical studies have indicated that women exhibit more robust food cravings. According to Trimtone, it has the ability to assist with this matter. Trimtone fat burner purports to curtail cravings and diminish appetite, thereby enabling one to attain their desired weight objectives. The product has been formulated while considering women leading a hectic lifestyle, as there arises no compulsion to adhere to a strict timetable. Simply ingest a singular pill on a daily basis. Working Appetite Suppressant As previously indicated, research studies have established that females exhibit a greater susceptibility toward food cravings when compared to their male counterparts. This exacerbates further while adhering to a low-calorie regimen. Hence, Trimtone incorporates glucomannan in its formulation, which facilitates appetite suppression and prevents inter-meal snacking. Reduced food cravings entail a decrease in snacking, leading to the effective elimination of body fat and effortless attainment of your desired body weight. Related Read: Best Weight Loss Pills In Ireland Triggers Thermogenesis Thermogenesis takes place when the body's internal temperature experiences an elevation. The organism endeavors to restore its normal temperature by metabolizing calories and converting adipose tissues into utilizable energy. When the process of thermogenesis is initiated, it elevates the body's metabolic rate, consequently leading to a higher caloric burn. Caffeine and green coffee are the constituents that facilitate the attainment of the aforementioned objective. They have been demonstrated to promote weight loss. Energy Boost Enhanced levels of energy enable one to perform more strenuously during physical activity. Trimtone has the potential to enhance your vigor and stamina through a unique combination of specially chosen constituents. Trimtone contains a significant concentration of caffeine. This will enable you to remain attentive and lively throughout the day. Ingredients Caffeine Green Coffee and Tea Glucomannan Grains of Paradise Dosage Trimtone represents a conveniently consumable addition to the category of dietary supplements, seeking as it does to facilitate optimal intake of only one capsule per diurnal cycle. To achieve optimal weight loss outcomes, it is recommended to consume one capsule prior to breakfast in the morning. Negative Effects This particular dietary supplement is considered to be among the most exceptional options available in the market. The product comprises natural constituents that have undergone scientific verification for their efficacy in facilitating fat burning and loss of fat. Purchase and Price Trimtone belongs to the higher price bracket of weight loss supplements. However, the greater quantity of items purchased yields an enhanced value proposition. Upon opting for certain bundled packages, additional boxes will be made available to you only at the official website. This proposition appears to be quite advantageous, as in the event the fat burner proves efficacious for the user, it is likely to be used over an extended period of time. Availing a bundled offer inclusive of a complimentary box shall suffice your requirement for several months. Each container comprises a total of 30 tablets. Please find below the available purchase alternatives: The cost of a one-month quantity would amount to $49.95. Avail a two-month supply of our product, and receive a complimentary box at no extra cost for a total price of $99.90. A 3-month stock inclusive of 2 complementary boxes is being offered at the price of $149.85. Refund Policy When a purchase is made through the official website, there is an assurance of a 100% guarantee on each order. This entails that in the event of product dissatisfaction, you reserve the option of returning the same after a 100-day duration, which is significantly greater than the return policy period of other fat-burning supplements, and receive a full refund of your purchase price. 5. PrimeShred - Best Fat Burner for Men to Jardiance Alternative A supplement called PrimeShred aids in weight loss and helps users develop lean, muscular bodies. It also contains a number of other ingredients. They get in shape, and their muscles are highlighted by doing this. Click Here to Get PrimeShred From Its Official website Ingredients PrimeShred is a vegan product. There are several potent natural ingredients in it, including: DMAE L-Theanine L-tyrosine. Vitamins B caffeine. Rhodiola Rosea Cayenne pepper. Bioperine. Working The flab that conceals people's muscular bodies can be lost with PrimeShred. It enhances the body's metabolism, causing the body to burn fat and produce energy. This additional energy can be used by individuals to exert more effort in the gym. Side Effects According to the manufacturer, there are no side effects that are known or reported. Before ingesting any health supplements, people should speak with a physician. Be cautious around the people listed below: Women who are expecting or nursing. Individuals who are allergic to any of the ingredients. Individuals with ongoing medical conditions. Children who are under 18 years old. Dosage Three pills per day are advised. On supplement dosage and other matters, a doctor can provide better guidance. Purchase and Price PrimeShred is only available from the official website. Any stock that has been listed elsewhere is not real and might be fake. Each tub contains 90 capsules and is good for one month. The costs are:. US$49.19.99 for a single tub. Three tubs cost US$99.99. 149.99 for five tubs. Refund Policy PrimeShred is a reputable product that can deliver positive outcomes. It appears to function well based on several satisfied reviews on the official website. Customers who are not happy with the product are entitled to a full refund. Every official purchase comes with a money-back guarantee. Within 100 days of the purchase, email support@primeshred.com. Jardiance Weight Loss - Conclusion Jardiance is not suitable for everyone. If you are considering using a weight loss pill then these five Jardiance weight loss alternatives are available over the counter without prescription. Contact Details Melissa support@jollofnews.com

May 11, 2023 02:35 AM Eastern Daylight Time

Article thumbnail News Release

Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies

Dermata Therapeutics

Dermata Therapeutics chairman and CEO Gerald Proehl takes Proactive's Stephen Gunnion through the clinical-stage biotechnology company's pipeline of treatments focused on medical and aesthetic skin conditions. He says the company's lead candidate DMT310 will move into Phase 3 studies once it gets the go-ahead from the US Food and Drug Administration (FDA) - a major milestone for Dermata. The acne treatment is the first product candidate being developed from the company's Spongilla technology platform. DMT410 uses its Spongilla technology as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 10, 2023 11:46 AM Eastern Daylight Time

Video
Article thumbnail News Release

Alpha Cognition's latest financial growth highlighted by new listing on Canadian Stock Exchange

Alpha Cognition

Alpha Cognition CEO Michael McFadden joins Natalie Stoberman from the Proactive studio to discuss the company's latest financial growth from new funding and reduced expenses and how its been highlighted by a new listing on the Canadian Stock Exchange. Alpha Cognition is a clinical stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 10, 2023 10:54 AM Eastern Daylight Time

Video
Article thumbnail News Release

Regular Skin Checks Are the Key to Melanoma Detection

YourUpdateTV

May is Melanoma Awareness Month, so it’s time to talk about melanoma, one of the deadliest forms of skin cancer. Melanoma claims the lives of more than 7,000 Americans each year – almost one every hour – and most cases are caused by sun exposure. Recently, Board Certified Dermatologists, Dr. Julie Karen and Dr. Amy Spizuoco, teamed with DermTech to discuss the disease, the importance of regular skin checks, and technology that can help enhance detection. A video accompanying this announcement is available at: https://youtu.be/LgppRu6_HTc It’s important to know the warning signs of skin cancer, and that sun safety and skin checks should be routine. The ABCDEs of melanoma (asymmetry, border, color, diameter and evolving) are often the characteristics of skin damage that doctors look for when identifying possible melanomas. In order to catch melanoma early, it’s recommended people schedule regular skin exams with their dermatologists. When melanoma is detected early, the five-year survival rate is >99%, but it drops to 27% once it spreads distantly. The traditional pathway for melanoma detection often involves doctors relying on the appearance of a mole and skin biopsies to determine its likelihood of being malignant. Skin biopsies have only a 5% melanoma diagnosis rate, meaning many skin biopsies are unnecessary. Fortunately, technology is changing the way suspicious moles are evaluated. The DermTech Melanoma Test uses a non-invasive Smart Sticker™ to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with the disease. A negative test result means there is a greater than 99% probability that the mole is not melanoma. For more information, visit DermTech.com About Dr. Julie Karen Dr. Julie Karen is a board-certified dermatologist who specializes in Mohs micrographic surgery, laser surgery, skin cancer, cosmetic dermatology and the treatment of leg veins. Dr. Karen graduated summa cum laude from Princeton University, where she was elected to Phi Beta Kappa and played varsity soccer. She received her medical degree from the Weill Medical College of Cornell University where she was elected to Alpha Omega Alpha, the national medical honors society, and graduated first in her class. Dr. Karen received the Clarence C. Coryell Prize for highest achievement in medicine, the John Metcalf Polk Prize for top scholastic performance, and the Janet M. Glasgow Memorial Award given to the top female graduate. She completed her residency training at The Ronald O. Perelman Department of Dermatology at New York University Medical Center where she served as Chief Resident and received the Morris Leider Award for Excellence in Dermatology. Dr. Karen completed a Procedural Dermatology Fellowship at NYU and Memorial Sloan-Kettering. Dr. Karen is certified by the American Board of Dermatology. She is a Fellow of the American Academy of Dermatology, the American College of Phlebology, the American Society of Dermatologic Surgery and the American Society for Laser Medicine & Surgery. She is affiliated with New York University Langone Medical Center, where she is a Clinical Assistant Professor of Dermatology and teaches surgery to the dermatology residents. About Dr. Amy Spizuoco Dr. Amy Spizuoco is a board-certified dermatologist and dermatopathologist. She did her undergraduate training at SUNY Binghamton, majoring in Italian and Biology. She then went to medical school at the NY College of Osteopathic Medicine.After medical school, she completed her dermatology residency at LECOM/Alta Dermatology in Arizona. During that time, she studied skin cancer surgery, pediatric dermatology at Phoenix Children’s Hospital and attended Dermatology Grand Rounds at Mayo Clinic in Scottsdale. After residency, Dr. Spizuoco went back to NY to complete a dermatopathology fellowship at the Ackerman Academy of Dermatopathology.Dr. Spizuoco has been practicing medical, surgical and cosmetic dermatology, as well as dermatopathology in Manhattan for 8 years. She is the President of the American Osteopathic College of Dermatology and is an Associate Clinical Instructor in the Department of Dermatology at The Icahn School of Medicine at Mount Sinai. She is also on the editorial board of Practical Dermatology and Dermatology Times. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 10, 2023 09:37 AM Eastern Daylight Time

Video
Article thumbnail News Release

Doceree Further Expands Global Footprint, Forays Into 8 South East Asian Markets With its Exclusive Partnership With Hello Health Group

Doceree

In keeping with its commitment to transform HCP messaging globally, Doceree, a global platform building unprecedented solutions for HCP programmatic marketing with proprietary data tools, today announced its long-term partnership with Hello Health Group, a leader in health & wellness content development that drives consumer and patient engagement. The latest collaboration will accelerate growth for both companies by combining the world-class HCP targeting and reach capabilities of Doceree with Hello Health’s leading patient and consumer reach and engagement solutions, and strong geographical presence in the South East Asian region. The partnership further establishes Doceree’s presence in eight key markets – Vietnam, Indonesia, Malaysia, Cambodia, Myanmar, Singapore, Philippines and Taiwan. The company bolstered its operations in the US, India, the European and the Middle East region and reached over 2 million HCPs in 20+ markets, becoming the only platform to provide such a vast targeted HCP reach globally. “We continue to look for innovative partnerships that help us grow our geographical footprint and be at the forefront of programmatic HCP messaging in the pharma marketing category. It is our commitment to empower our partners with the capability of targeting and reaching HCPs effectively across the globe with our deep and innovative technological expertise. The Doceree-Hello Health collaboration is a strong one in the South East Asian region, opening doors for pharma companies to engage physicians in the most effective and regulatory-compliant manner,” said Harshit Jain MD, Founder & Global CEO - Doceree. Doceree’s proprietary HCP-identification technology will enable Hello Health to expand its capabilities to target and reach prescribers efficiently for showcasing them messages from pharma brands. “This is a pioneering partnership and we are glad to introduce, for the first time in the Asia Pacific region, such a revolutionary technology-based solution to reach HCPs. Doceree’s programmatic platform is built in such a manner that it adapts to different markets’ requirements and needs. Also, most importantly, it is compliant with regulations existing in those markets. As a team, we will unlock the full potential of programmatic messaging and engagement with HCPs in SEA and bring the best ROI to our clients in the new evolving digital healthcare ecosystem,” said Bertrand Sauvageon, CEO - Hello Health Group. This latest partnership intends to create great value for both companies and their shareholders and lay down a path of success and growth for their respective clients and partners. About Doceree Doceree, the world's first global network of physician-only platforms, offers a cutting-edge solution to programmatically reach HCPs where they consume information on professional platforms, including medical journals, education platforms, and physician networks.Its proprietary physician identity resolution technology, ESPYIANTM, allows brands to showcase the right information to the right physician at the most opportune moments based on their specialty, location, and professional interests. To learn more, visit doceree.com. About Hello Health: Hello Health’s ambition is to orchestrate the leading ecosystem of digital health solutions in South East Asia, empowering millions of people to manage their health in a cost-effective and highly convenient way.With over 34m unique monthly users, 93% organic/direct traffic, 12m social media followers, and over 100,000 pieces of medically reviewed, relevant, and engaging content in 9 local languages, Hello Health is the clear leader in health & wellness content development to drive consumer & patient engagement. To learn more, visit https://hellohealthgroup.com/ Contact Details Kyle Murray +91 70420 89805 kyle@kitehillpr.com Company Website https://doceree.com/us/

May 10, 2023 09:34 AM Eastern Daylight Time

Article thumbnail News Release

AMERICAN DIVERSIFIED HOLDINGS CORPORATION ANNOUNCES COMPLETION OF 324.5 MILLION SHARES CANCELLATION

American Diversified Holdings Corp.

American Diversified Holdings Corporation (OTC: ADHC) announced today a corporate update regarding recent developments with the company. The Transfer Agent has received the formal court order from the Eighth Judicial Circuit Court, Clark County, Nevada, Case Number A-21-843670-B formally ordering the cancellation of 324.5 million shares of common stock. Shareholders seeking the exact capitalization structure can visit www.OTCMarkets.com SHARE CANCELLATION: ADHC filed suit in The Eight Judicial Circuit Court, Clark County, Nevada, Case Number A-21-843670-B, seeking the cancellation of 324,500,000, (324.5 MM) shares of common stock. On January 6, 2023, the court granted the motion for default. On a scheduled hearing on April 17th, 2023 the court granted the default judgment, and all litigation is now resolved. Currently, ADHC capitalization structure is as follows: Shares Outstanding: 779,993 mm Shares Restricted: 195,811 mm Shares in the Float: 584,181 mm "All litigation is resolved which now paves the way for ADHC to launch a comprehensive business transformation", commented ADHC management. "We now have a clean slate with no impediments to the growth of our company. Building shareholder value is now the primary focus of ADHC operations". American Diversified Holdings Corporation operates two e-commerce sites focused on emerging technologies: www.universalwellnesshc.com and www.RollsChoiceAdhesives.com. The business model includes selling products to consumers, driving traffic to partner sites, generating ad revenue, and creating partnership opportunities for other wellness companies. Universal Wellness is a wellness and lifestyle e-commerce site focused on providing innovative products, news, and the latest healthcare developments for consumers nationwide. Rolls Choice™ Southern California-based manufacturer, distributor, and e-commerce company selling an all-natural Adhesive Glue and application device sold on Amazon.com (product number 972978083) and on its own website. Investor Contact: https://www.adhcinvestor.com TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different from the performance or achievements expressed. You should not place undue reliance on these statements since they involve known and unknown risks, in some cases, beyond our control. Contact Details Investor Contact: +1 858-405-7168

May 10, 2023 09:28 AM Eastern Daylight Time

Article thumbnail News Release

Colon Cancer Creeping Into Younger Adults - New R&D Uncovers Early Signs

MarketJar

Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are ineligible for colonoscopies. The most concerning early indicator of colon cancer is rectal bleeding, which is taboo to talk about outside of the bathroom. According to Dr. Matthew Kalady in a recent NBC News article, head of the division of colon and rectal surgery at the Ohio State University Comprehensive Cancer Center, "It can be difficult or embarrassing to talk about." However, he added, "the reality is that everyone deals with something like this," and it's crucial to know what's typical and what isn't. 5,075 people with early-onset colorectal cancer were included in the new study from Washington University School of Medicine in St. Louis, which was published Thursday in the Journal of the National Cancer Institute. The intention was to identify symptoms that could serve as warning signs for colorectal cancer, a condition that has been on the rise in younger individuals in recent years but whose alarmingly high rate of late-stage diagnosis warrants concern. The percentage of colorectal cancer diagnoses involving individuals under the age of 55 quadrupled from 1995 to 2019, from 11% to 20%, according to the American Cancer Society. Up to two years before a colon cancer diagnosis, the current study identified four different signals: Abdominal pain. Rectal bleeding. Ongoing diarrhea. Anemia due to iron deficiency. At least one of the symptoms, which could have started up to two years prior to a diagnosis, was experienced by participants. However, a colonoscopy is only advised at or after the age of 45. This implies that patients may have symptoms for a long time before seeking medical attention or receiving a colon cancer diagnosis, which is treatable if discovered early. The study's lead author, Dr. Cassandra Fritz, an assistant professor of medicine in the division of gastrointestinal at the Washington University School of Medicine, said, "As patients, we kind of brush these things away." At least one of such symptoms was present in nearly half of the study subjects three months before their diagnoses. Additional symptoms increased the likelihood of a cancer diagnosis. The study, according to fellow author Yin Cao, an associate professor of surgery in the department of public health sciences at Washington University School of Medicine, indicates an "alarming problem" for young adults and the medical professionals who treat them. “Young folks need to be aware of these indicators”, Cao stated in an interview, and “this is the message we are making loud and clear.” Committed to Saving Lives by Improving At-Home Cancer Detection A non-invasive, quick, easy, and accurate colorectal detection test is available from Mainz Biomed (NASDAQ:MYNZ). Stool tests are more accurate than blood tests and may be performed in the comfort of your own home, making them a more practical choice. In addition to early colon cancer detection, on May 10th Mainz Biomed announced a partnership with Microba Life Sciences for the Development of PancAlert. The combination of DNA and microbiome biomarkers has the potential to improve the technical profile of a novel pancreatic cancer screening test. A collaborative research initiative is underway to identify disease-specific microbiome biomarkers. With ColoAlert already out in the market, PancAlert looks to be another monumental tool helping savr lives from pancreatic cancer. The company's core product, ColoAlert, is an at-home colorectal cancer (CRC) screening kit with high sensitivity and specificity. Patients are given a basic kit that includes directions, a stool collector, and mailing instructions so they can mail the kit back to their local lab for testing and results. This non-invasive test can identify malignancies earlier than fecal occult blood tests (FOBT) by analyzing tumor DNA. ColoAlert, a stool test that uses PCR technology, finds more cases of colorectal cancer than traditional stool tests and enables early detection. Through a network of top independent laboratories, corporate health initiatives, and direct sales, this screening test is CE marked and is commercially available in a number of European countries. To receive commercial approval in the US, ColoAlert will be examined in the FDA-registered trial "ReconAAsense." Once licensed in the United States, the Company's commercial objective is to build scalable distribution across the nation through a cooperative partner program with local and national laboratory service providers. For the processing of the ColoAlert PCR test kit, Mainz Biomed (NASDAQ:MYNZ) has expanded its network of lab partners to include Eurofins GeLaMed. A division of the global laboratory corporation Eurofins Scientific, which does 450 million tests annually and employs over 61,000 people in 61 nations, is Eurofins GeLaMed. Germany is home to four of its locations. Eurofins GeLaMed offers cutting-edge diagnostics in human genetics, medical microbiology, laboratory medicine, and molecular diagnostics across eleven medical specialties. The more than 500 staff of GeLaMed process more than 15,000 orders daily and offer more than 2,000 analytical procedures from their portfolios in laboratory medicine and microbiology, all under the supervision of medical specialists. Marcus Cholewa, Director of Clinical Diagnostics for Eurofins Business Line in DACH, expressed enthusiasm for the partnership between Mainz Biomed and Eurofins GeLaMed because Eurofins consistently offers the highest levels of quality, customer service, and the most thorough testing methodologies. Additionally, he said that Eurofins has a track record of offering innovative and high-quality diagnostic testing solutions, and that by collaborating, they could be able to detect colorectal cancer (CRC) and give patients individualized information to help them manage their health. In order to raise awareness of the importance of early screening for CRC identification and prevention, Mainz Biomed (NASDAQ:MYNZ) will support physician and patient education programs during March Colorectal Cancer Awareness Month and Eurofins GeLaMed will provide ColoAlert at its testing locations. Additionally, Mainz Biomed has expanded its network of lab partners across Europe and a few overseas markets by including the Instituto de Microecologia in Madrid. For more than 60 years, the Instituto de Microecologia has been a leader in the study of the microbiota and food sensitivity, emphasizing the importance of intestinal health through microbiological investigation, microbiota profile diagnosis, and specialized health indicators. The company's ongoing expansion in Europe may be seen in Mainz Biomed's entry into the market and commercialization in Spain and Portugal. Visit this link to learn more about Mainz Biomed (NASDAQ:MYNZ) and its initiatives. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) seventy three thousand three hundred forty USD for 17 days (13 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 10, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

MGC Pharmaceuticals makes good progress with CimetrA and CannEpil treatments

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals chief commercial officer Robert Clements joined Proactive's Stephen Gunnion with details of the company's activity in the first quarter of 2023, as well as upcoming milestones. Clements noted that clinical trials of its CimetrA drug continue to demonstrate anti-inflammatory effects, with the results set to be used in a US new drug submission, adding that the US market holds significant potential for the company. This year, he said the company will also focus on expanding access to CannEpil in Europe, and advancing its cannabinoid-based investigational products. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 10, 2023 04:16 AM Eastern Daylight Time

Video
Article thumbnail News Release

Monogram Orthopedics Plans NASDAQ Listing After Reg A+ Funding Round Concludes

Monogram Orthopedics

Monogram Orthopedics will conclude their Reg A+ funding round in preparation for their planned Nasdaq listing under the reserved ticker symbol “MGRM.” Monogram is working to develop patient-optimized, 3D-printed orthopedic implants enabled by robotics with advanced pre-operative imaging. Investors who wish to participate in the offering can subscribe at Monogram Orthopedics |Reg A+ Investment and hit the invest now button after reviewing the Company’s offering documents. The ability to subscribe to the offering on the Company’s site will conclude on May 10, 2023. Approximately 1.7 million patients receive knee replacement surgeries each year, but up to 20% experience chronic pain after the procedure. In addition, 40% of total knee replacement revision surgeries are caused by mechanical loosening, showing a need to improve knee implants for better fixation. Because of this, one-in-five patients report high levels of dissatisfaction after their procedure, with over a third of patients (36%) reporting they wouldn’t choose to have the procedure if they could do it again. Monogram Orthopedics plans to address these issues by 3D-printing FDA-approved implants tailored to each patient's unique anatomy. They are developing low-latency active-milling robots to make the precise cuts needed for custom implants, which aims to reduce the number of incisions and bone loss during surgery. “By 2027 50% of knee replacement surgeries will be performed robotically. Monogram is currently the only company offering FDA-approved, 3D printed, patient-specific implants that, in the future, will be inserted with active milling robots,” Benjamin Sexson, CEO of Monogram Orthopedics said. “With the coming close of our current Reg A+ funding round we are happily looking forward to our planned public listing. We imagine our investors will be just as excited as we are to one day see ‘MRGM’ scrolling on the ticker outside the NASDAQ exchange’s building in Times Square,” he added. “Having been a critical part of the Monogram development and heavily involved in building the formative technology as the Company's longest-tenured employee, I can say on behalf of myself and my colleagues that this planned listing will be a tremendous accomplishment. It has been an honor to help push this engineering effort and to have had the opportunity to play such a critical role in developing this transformative product.” Sanath Vurelli, Senior Robotics Engineer, at Monogram Orthopedics said. The company recently demonstrated a total knee replacement surgery by a surgeon operating in New York City on a cadaver patient in Austin, Texas. Their 3D-printed replacement’s patented design facilitates a bone-to-implant bond so they do not rely on bone cement. ABOUT MONOGRAM ORTHOPEDICS Monogram Orthopedics is working to develop a product solution architecture with the long-term goal to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The Company has a robot prototype that can autonomously execute optimized paths for high precision insertion of implants in synthetic bone specimens. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The Company has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for any of its robotic products. FDA approval is required to market these products, and the Company has not obtained FDA approval for any of its robotic products, and it cannot estimate the timing, or assure the ability, to obtain such clearances. Monogram Orthopedics changing the way orthopedic surgery is done. Our system combines personalized knee implants with precision robotic surgical assistants, giving patients a better-fitting knee replacement with minimally invasive surgery. 100,000 knee replacements failing each year in a $19.4B market, represents an enormous opportunity for us. This press release may include ''forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopedics Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' Although Monogram Orthopedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Monogram are highly speculative. Investing in shares of Monogram involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. Monogram intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Monogram, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular: https://www.sec.gov/Archives/edgar/data/1769759/000110465923024829/tm237645d1_partiiandiii.htm DealMaker Securities, LLC is being compensated a 4% commission from the lead Selling Agent engaged by Monogram Orthopedics Inc. The Company has engaged Digital Offering, LLC (“Digital Offering”) to act as lead selling agent (which we sometimes refer to as the “Selling Agent”) to offer the shares of our common stock, par value $0.001 (the “Common Stock”) to prospective investors in this offering on a “best efforts” basis, which means that there is no guarantee that any minimum amount will be received by the Company in this offering. The Company will pay a cash commission of 7.00% to Digital Offering on sales of the shares of Common Stock. See “Plan of Distribution” in the Offering Circular for details of compensation payable to the Selling Agent in connection with the offering. DealMaker Securities, LLC is not affiliated with other companies mentioned herein. Contact Details Monogram Orthopedics Loreana Davi +1 512-790-5151 info@monogramorthopedics.com Company Website https://invest.monogramorthopedics.com/

May 09, 2023 10:58 AM Eastern Daylight Time

1 ... 125126127128129 ... 302